Skip to main content
. 2021 Oct 8;2021(10):CD011611. doi: 10.1002/14651858.CD011611.pub3

NCT01881763.

Study name Ketamine as an augmentation strategy for electroconvulsive therapy (ECT) in depression
Methods Double‐blind, parallel randomised controlled trial
Participants DSM‐IV unipolar or bipolar depression, 18‐70 years
HRSD > 21 pre‐treatment
MADRS > 19 at screening
Interventions Ketamine versus methohexital (both IV)
Outcomes Time to achieve remission (HRSD‐24)
Cognitive side effects
Starting date June 2010
Contact information Contact: Styliani Kaliora, M.D. skaliora@nshs.edu
Notes Recruiting